Lazertinib,
1903008-80-9,
UNII-4A2Y23XK11,
4A2Y23XK11,
GNS-1480,
YH25448,
N-(5-((4-(4-((Dimethylamino)methyl)-3-phenyl-1H-pyrazol-1-yl)pyrimidin-2-yl)amino)-4-methoxy-2-morpholinophenyl)acrylamide,
N-[5-[[4-[4-[(dimethylamino)methyl]-3-phenylpyrazol-1-yl]pyrimidin-2-yl]amino]-4-methoxy-2-morpholin-4-ylphenyl]prop-2-enamide,
Lazertinib [INN],
SCHEMBL17670400,
GTPL10136,
GNS1480,
lazertinib-yh25448-gns-1480,
RRMJMHOQSALEJJ-UHFFFAOYSA-N,
EX-A1912,
Lazertinib (YH25448,GNS-1480),
YH-25448,
Compound 73 [WO2016060443A2],
HY-109061,
AK00779508,
CS-0032992,
A16827,
2-Propenamide, N-(5-((4-(4-((dimethylamino)methyl)-3-phenyl-1H-pyrazol-1-yl)-2-pyrimidinyl)amino)-4-methoxy-2-(4-morpholinyl)phenyl)-,
N-(5-(4-(4-((dimethylamino)methyl)-3-phenyl-1H-pyrazol-1-yl)pyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamide,